IQVIA Holdings Inc.
IQVBusiness Overview
ticker: IQV step: 01 generated: 2026-05-12 source: quick-research
IQVIA Holdings (IQV) — Business Overview
Business Description
IQVIA Holdings is the world's largest Contract Research Organization (CRO) and healthcare data/analytics company, formed from the merger of IMS Health and Quintiles in 2016. The company serves pharmaceutical, biotech, and medical device companies by conducting clinical trials (Phase I–IV), managing regulatory submissions, and providing health data analytics used for commercial insights, market research, and real-world evidence. IQVIA holds an estimated 38% global CRO market share, operates in 100+ countries, employs ~88,000 people, and holds a database of 1.2 billion unique non-identified patient records.
Revenue Model
IQVIA generates revenue primarily through long-term service contracts: clinical research contracts (typically 2–5 years per study) for its R&DS segment, and multi-year data/analytics/software subscriptions for its TAS segment. Revenue is recognized as services are delivered (percentage of completion for clinical trials; subscription/delivery basis for TAS). The large backlog ($32.7B+ in R&DS as of late 2025) provides strong revenue visibility 2–3 years forward. IQVIA's "IQVIA Connected Intelligence" platform — combining clinical, commercial, real-world data, and AI tools — creates an integrated technology moat that drives enterprise stickiness.
Products & Services
R&DS (Research & Development Solutions, ~55% of revenue):
- Phase I–IV clinical trial management (patient recruitment, site management, data collection, biostatistics)
- Regulatory affairs support (NDA/BLA/MAA submissions)
- Post-approval studies and real-world evidence (RWE) studies
- Contract functional services (embedded CRO capabilities within sponsor organizations)
- AI-powered trial design and patient identification tools
TAS (Technology & Analytics Solutions, ~40% of revenue):
- Healthcare intelligence databases (prescription data, claims, EHR, medical device data)
- Commercial insights and salesforce effectiveness tools
- Real-world evidence analytics
- AI/ML applications built on the 1.2B patient record database
- Cloud-based CRM and SaaS applications for pharma commercial teams
CSMS (Contract Sales & Medical Solutions, ~5% of revenue):
- Contract sales force deployment for pharmaceutical companies
Customer Base & Go-to-Market
IQVIA serves all 20 of the top 20 global pharmaceutical companies, hundreds of mid-size and specialty biotech companies, and government health agencies. 19 of the top 20 pharma companies operate AI agents that IQVIA built inside their own workflows — creating deep integration. Revenue is global, with North America ~50%, Europe ~30%, and Asia-Pacific ~20%.
Competitive Position
IQVIA is the global CRO market leader, competing with ICON plc (#2), Labcorp Drug Development (formerly Covance), PPD (Thermo Fisher), PRA Health Sciences (ICON), and Syneos Health. Its competitive advantages include the largest global site and investigator network, the world's most comprehensive healthcare data assets (used by both TAS and R&DS), and deep AI/technology capabilities across both segments. The integration of commercial data intelligence with clinical trial execution creates cross-selling opportunities unavailable to pure-play CROs.
Key Facts
- Founded: 2016 (merger of IMS Health and Quintiles Transnational)
- Headquarters: Durham, North Carolina
- Employees: ~88,000
- Exchange: NYSE
- Sector / Industry: Healthcare / Life Sciences Tools & Services (CRO)
- Market Cap: ~$20B
Financial Snapshot
ticker: IQV step: 04 generated: 2026-05-12 source: quick-research
IQVIA Holdings (IQV) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $14.41B | $14.98B | $15.41B | +2.8% |
| Gross Margin | ~34.9% | ~34.9% | ~34.9% | flat |
| Operating Margin | ~10.5% | ~11.0% | ~10.5% | -0.5pp |
| Net Income (GAAP) | ~$1.1B | ~$1.1B | ~$1.3B | +18% |
| Adjusted Diluted EPS | ~$8.80 | $10.20 | ~$11.20 | +9.8% |
Note: GAAP EPS includes amortization of acquired intangibles (~$1.5B annually) from the 2016 IMS/Quintiles merger, making Adjusted EPS the primary management metric. FY2024 adjusted EPS growth was "high single-digit" on 2.8% revenue growth, with margin expansion. Gross margin is remarkably stable at ~34.9% due to the long-term nature of service contracts.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$2.2B |
| Free Cash Flow | ~$1.7B |
| Cash & Equivalents | ~$1.7B |
| Total Debt | ~$13.0B |
Note: IQVIA carries significant debt (~5x net leverage at peak) from the 2016 merger. The company is deleveraging: repurchased $1.35B in shares in FY2024 while lowering net leverage ratio year-over-year. FCF conversion is strong (>100% of net income).
Key Ratios (approximate)
- P/E: ~14x (FY2024 GAAP) | EV/EBITDA: ~12x | FCF Yield: ~8%
- Revenue Growth (FY2024): +2.8% | Adjusted EBITDA Margin: ~20–21%
- Dividend Yield: none (company prioritizes buybacks and debt paydown)
Growth Profile
IQVIA's revenue growth has been moderate (3–6% organically) reflecting the pace of pharma/biotech clinical outsourcing and healthcare data spending. R&DS backlog of $31.1B (FY2024) and $32.7B (later 2025) provides 2-year revenue visibility and is growing 5.5% YoY — a leading indicator of accelerating revenue growth. TAS (data/analytics) has grown 8–10% annually, faster than clinical services. FY2025 revenue reached $16.31B (+5.9%), with FY2026 guidance of $17.15B–$17.35B, implying 5–7% growth driven by backlog burn and recovering biotech funding.
Forward Estimates
- FY2025 (actual): Revenue $16.31B; adjusted EPS ~$11.80–12.00
- FY2026E Revenue: $17.15B–$17.35B (company guidance); adjusted EPS ~$13–14 (consensus)
- Long-term: Adj. EBITDA margin expansion toward 23–25% as TAS (higher-margin) grows faster than R&DS
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $IQV.